141 related articles for article (PubMed ID: 37771433)
21. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
Kodack DP; Chung E; Yamashita H; Incio J; Duyverman AM; Song Y; Farrar CT; Huang Y; Ager E; Kamoun W; Goel S; Snuderl M; Lussiez A; Hiddingh L; Mahmood S; Tannous BA; Eichler AF; Fukumura D; Engelman JA; Jain RK
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3119-27. PubMed ID: 23071298
[TBL] [Abstract][Full Text] [Related]
22. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
[TBL] [Abstract][Full Text] [Related]
23. Targeted Therapies for Brain Metastases from Breast Cancer.
Venur VA; Leone JP
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142
[TBL] [Abstract][Full Text] [Related]
24. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
[TBL] [Abstract][Full Text] [Related]
25. Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer.
Graff SL; Yan F; Abdou Y
Clin Breast Cancer; 2023 Oct; 23(7):e380-e393. PubMed ID: 37407378
[TBL] [Abstract][Full Text] [Related]
26. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
27. Management of breast cancer brain metastases: Focus on human epidermal growth factor receptor 2-positive breast cancer.
Yuan P; Gao SL
Chronic Dis Transl Med; 2017 Mar; 3(1):21-32. PubMed ID: 29063053
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
29. Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies.
Chiec L; Kumthekar P
CNS Drugs; 2022 Feb; 36(2):167-179. PubMed ID: 35075602
[TBL] [Abstract][Full Text] [Related]
30. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
31. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
32. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients.
Fan Y; Huang Z; Fang L; Miu L; Lin N; Gong L; Yu H; Yang H; Mao W
Onco Targets Ther; 2013; 6():1789-803. PubMed ID: 24353431
[TBL] [Abstract][Full Text] [Related]
34. Management of breast cancer brain metastases.
Takahashi H; Isogawa M
Chin Clin Oncol; 2018 Jun; 7(3):30. PubMed ID: 30056732
[TBL] [Abstract][Full Text] [Related]
35. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
36. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
38. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
39. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer.
Najjar MK; Manore SG; Regua AT; Lo HW
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360302
[TBL] [Abstract][Full Text] [Related]
40. Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment.
Koo T; Kim IA
Radiat Oncol J; 2016 Mar; 34(1):1-9. PubMed ID: 27104161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
